Sanders Morris Harris’s Xenon Pharmaceuticals XENE Stock Holding History

Sanders Morris Harris’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,500	Closed	-$1.25M	–	280
2026 Q1	$1.25M	Buy	+21,500	New	+$991K	0.2%	99
2025 Q4	–	Sell	-21,500	Closed	-$863K	–	293
2025 Q3	$863K	Buy	+21,500	New	+$757K	0.11%	122
2025 Q2	–	Sell	-21,500	Closed	-$659K	–	302
2025 Q1	$659K	Hold	21,500	–	–	0.1%	131
2024 Q4	$843K	Hold	21,500	–	–	0.13%	115
2024 Q3	$846K	Hold	21,500	–	–	0.14%	105
2024 Q2	$838K	Hold	21,500	–	–	0.14%	103
2024 Q1	$926K	Hold	21,500	–	–	0.17%	94
2023 Q4	$1.03M	Hold	21,500	–	–	0.51%	51
2023 Q3	$718K	Hold	21,500	–	–	0.15%	105
2023 Q2	$822K	Buy	+21,500	New	+$855K	0.18%	83
2023 Q1	–	Sell	-21,500	Closed	-$848K	–	248
2022 Q4	$848K	Hold	21,500	–	–	0.32%	66
2022 Q3	$778K	Sell	21,500 -3,000	-12%	-$108K	0.19%	85
2022 Q2	$754K	Buy	+24,500	New	+$741K	0.17%	94
2022 Q1	–	Sell	-24,500	Closed	-$771K	–	339
2021 Q4	$771K	Hold	24,500	–	–	0.13%	117
2021 Q3	$770K	Hold	24,500	–	–	0.14%	114
2021 Q2	$455K	Hold	24,500	–	–	0.09%	183
2021 Q1	$432K	Hold	24,500	–	–	0.09%	179
2020 Q4	$374K	Hold	24,500	–	–	0.09%	194
2020 Q3	$288K	Buy	+24,500	New	+$288K	0.08%	210

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Sanders Morris Harris's XENE Position: Q2 2026 in Review

Sanders Morris Harris sold out of Xenon Pharmaceuticals (XENE) in Q2 2026, closing a stake of 21,500 shares — an estimated $1.25M sold.

Sanders Morris Harris first reported a position in XENE in Q3 2020 and held it in 19 quarters. The position peaked at $1.25M in Q1 2026. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Sanders Morris Harris reported no remaining Xenon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Sanders Morris Harris sold 21,500 Xenon Pharmaceuticals shares in Q2 2026, an estimated $1.25M.
Sanders Morris Harris first reported a position in Xenon Pharmaceuticals in Q3 2020 and held it in 19 quarters.
Sanders Morris Harris's Xenon Pharmaceuticals position peaked at $1.25M in Q1 2026.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Sanders Morris Harris's 13F filing for Q2 2026, filed 7 Jul 2026.